Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) financials · P/E 40, rev $3.02B
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) P/E 40, rev $3.02B.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.02B | $2.79B |
| Cost of Revenue | $1.91B | $1.77B |
| Gross Profit | $1.11B | $1.02B |
| Operating Income | $394.1M | $249.3M |
| Net Income | $72.1M | -$116.9M |
| EPS (Diluted) | $0.22 | -$0.38 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $3.68B | $3.50B |
| Current Assets | $1.91B | $1.59B |
| Cash & Equivalents | $282.0M | $110.6M |
| Inventory | $606.3M | $612.5M |
| PP&E | $442.9M | $424.9M |
| Total Liabilities | $3.75B | $3.61B |
| Current Liabilities | $881.6M | $1.13B |
| Short-term Debt | $6.76M | $224.2M |
| Long-term Debt | $2.57B | $2.16B |
| Total Debt | $2.57B† | $2.39B† |
| Shareholders' Equity | -$70.8M | -$109.3M |
| Retained Earnings | -$535.0M | -$607.1M |
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $340.0M | $295.1M |
| CapEx | $70.1M | $51.9M |
| Investing Cash Flow | -$112.3M | -$63.0M |
| Financing Cash Flow | -$31.5M | -$211.8M |
| Net Change in Cash | $194.5M | $19.3M |
| Free Cash Flow | $269.9M | $243.2M |
FAQ
What is AMRX P/E and revenue?
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) P/E 40, rev $3.02B.
What is AMRX revenue?
Amneal Pharmaceuticals, Inc. Class A Common Stock last cached revenue is $3.02B (FY2025).
Is AMRX profitable?
Amneal Pharmaceuticals, Inc. Class A Common Stock last cached net income is $72.1M (FY2025).
What are AMRX total assets?
Amneal Pharmaceuticals, Inc. Class A Common Stock last cached total assets are $3.68B (FY2025).
What is AMRX free cash flow?
Amneal Pharmaceuticals, Inc. Class A Common Stock last cached free cash flow is $269.9M (FY2025).
Not investment advice. Cached statements, not a live tape.